1. Age <18 years 2. Pregnant women or breast-feeding mothers 3. Previous transfusion reaction or other contraindication to a plasma transfusion 4. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 5. Volume stress due to CP administration would be intolerable 6. Known IgA deficiency 7. Life expectancy < 6 months 8. Duration SARS-CoV-2 typical symptoms > 3 days 9. SARS-CoV-2 PCR detection older than 3 days 10. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria) 11. Previously or currently hospitalized due to SARS-CoV-2 12. Previous antiviral therapy for SARS-CoV-2 13. ALT or AST > 5 x ULN at screening 14. Accommodation in an institution due to legal orders (§40(4) AMG). 15. Any psycho-social condition hampering compliance with the study protocol. 16. Evidence of current drug or alcohol abuse.

1. Age <18 years 2. Pregnant women or breast-feeding mothers 3. Previous transfusion reaction or other contraindication to a plasma transfusion 4. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 5. Volume stress due to CP administration would be intolerable 6. Known IgA deficiency 7. Life expectancy < 6 months 8. Duration SARS-CoV-2 typical symptoms > 3 days 9. SARS-CoV-2 PCR detection older than 3 days 10. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria) 11. Previously or currently hospitalized due to SARS-CoV-2 12. Previous antiviral therapy for SARS-CoV-2 13. ALT or AST > 5 x ULN at screening 14. Accommodation in an institution due to legal orders (§40(4) AMG). 15. Any psycho-social condition hampering compliance with the study protocol. 16. Evidence of current drug or alcohol abuse.

1. Age <18 years 2. Unable to give informed consent 3. Pregnant women or breast-feeding mothers 4. Previous transfusion reaction or other contraindication to a plasma transfusion 5. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. Volume stress due to CP administration would be intolerable 7. Known IgA deficiency 8. Life expectancy < 6 months 9. Duration SARS-CoV-2 typical symptoms > 3 days 10. SARS-CoV-2 PCR detection older than 3 days 11. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. Previously or currently hospitalized due to SARS-CoV-2 13. Previous antiviral therapy for SARS-CoV-2 14. ALT or AST > 5 x ULN at screening 15. Liver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial) 16. Chronic kidney disease with GFR < 30 ml/min 17. Concurrent or planned anticancer treatment during trial period 18. Accommodation in an institution due to legal orders (§40(4) AMG). 19. Any psycho-social condition hampering compliance with the study protocol. 20. Evidence of current drug or alcohol abuse. 21. Use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. Previous use of convalescent plasma for COVID-19 23. Concomitant proven influenza A infection 24. Patients with organ or bone marrow transplant in the three months prior to Screening Visit

1. Age <18 years 2. Unable to give informed consent 3. Pregnant women or breast-feeding mothers 4. Previous transfusion reaction or other contraindication to a plasma transfusion 5. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 6. Volume stress due to CP administration would be intolerable 7. Known IgA deficiency 8. Life expectancy < 6 months 9. Duration SARS-CoV-2 typical symptoms > 3 days 10. SARS-CoV-2 PCR detection older than 3 days 11. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria). 12. Previously or currently hospitalized due to SARS-CoV-2 13. Previous antiviral therapy for SARS-CoV-2 14. ALT or AST > 5 x ULN at screening 15. Liver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial) 16. Chronic kidney disease with GFR < 30 ml/min 17. Concurrent or planned anticancer treatment during trial period 18. Accommodation in an institution due to legal orders (§40(4) AMG). 19. Any psycho-social condition hampering compliance with the study protocol. 20. Evidence of current drug or alcohol abuse. 21. Use of other investigational treatment within 5 half-lives of enrollment is prohibited 22. Previous use of convalescent plasma for COVID-19 23. Concomitant proven influenza A infection 24. Patients with organ or bone marrow transplant in the three months prior to Screening Visit

1. Age <18 years 2. Pregnant women or breast-feeding mothers 3. Previous transfusion reaction or other contraindication to a plasma transfusion 4. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 5. Volume stress due to CP administration would be intolerable 6. Known IgA deficiency 7. Life expectancy < 6 months 8. Duration SARS-CoV-2 typical symptoms > 3 days 9. SARS-CoV-2 PCR detection older than 3 days 10. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria) 11. Previously or currently hospitalized due to SARS-CoV-2 12. Previous antiviral therapy for SARS-CoV-2 13. ALT or AST > 5 x ULN at screening 14. Accommodation in an institution due to legal orders (§40(4) AMG). 15. Any psycho-social condition hampering compliance with the study protocol. 16. Evidence of current drug or alcohol abuse.

1. Age <18 years 2. Pregnant women or breast-feeding mothers 3. Previous transfusion reaction or other contraindication to a plasma transfusion 4. Known hypersensitivity to camostat mesylate and/or severe pancreatitis 5. Volume stress due to CP administration would be intolerable 6. Known IgA deficiency 7. Life expectancy < 6 months 8. Duration SARS-CoV-2 typical symptoms > 3 days 9. SARS-CoV-2 PCR detection older than 3 days 10. SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria) 11. Previously or currently hospitalized due to SARS-CoV-2 12. Previous antiviral therapy for SARS-CoV-2 13. ALT or AST > 5 x ULN at screening 14. Accommodation in an institution due to legal orders (§40(4) AMG). 15. Any psycho-social condition hampering compliance with the study protocol. 16. Evidence of current drug or alcohol abuse.